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corr e spondence
T h e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
HSV Therapy and HIV-1 Reduction
To the Editor: Nagot et al. (Feb. 22 issue)1 re-
port that treatment with valacyclovir (1 g per day) 
to suppress herpes simplex virus (HSV) reduced 
human immunodeficiency virus type 1 (HIV-1) 
RNA levels in patients in Burkina Faso. This find-
ing raises important questions regarding the clin-
ical management of HSV infection in poor coun-
tries. Of the 68 patients receiving valacyclovir, 
3 (4%) had at least one episode of vesicular or 
genital ulceration during the study period. In an-
other trial,2 which showed a reduction of recur-
rences of HSV type 2 (HSV-2) with valacyclovir (1 g 
per day) in HIV-infected patients, 3 (6%) of the 50 
HSV-2 isolates collected were resistant to acyclo-
vir. In Western countries, 5 to 6% of the HSV-2 
isolates from patients with immunosuppression 
are resistant to acyclovir.3 Treatment of such pa-
tients is challenging and may require intravenous 
foscarnet or cidofovir. However, none of these 
drugs are routinely available in poor countries 
such as Burkina Faso. The risk of emergence of 
resistant HSV strains raises important questions 
that must be considered.
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To the Editor: In the study by Nagot et al., 
which showed that treatment with valacyclovir 
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2.
3.
for HSV infection was associated with a reduction 
in HIV viral load in plasma and the genital tract, 
the viral load at baseline was higher in the placebo 
group, and the statistical analysis accounted for 
this factor. However, there was also an increase 
in the HIV viral load in the placebo group during 
the study, and most of the evolving difference in 
viral load between the study groups during treat-
ment may have been due to the increase in the 
placebo group. This increase, in turn, may have 
been due to other (e.g., gastrointestinal) infections 
and HIV-unrelated gastrointestinal disorders. (Di-
arrhea, vomiting, dysphagia, and constipation 
were reported in 26 patients in the placebo group 
vs. 13 in the valacyclovir group; P = 0.02.) Breach 
of the gastrointestinal epithelial barrier with the 
associated translocation of products of enteric bac-
teria such as lipopolysaccharide and butyrate1,2 
has been associated with systemic immune acti-
vation, which amplifies replication of HIV through 
nuclear factor-κB–mediated stimulation of long 
terminal repeats induced by tumor necrosis factor. 
In future studies, investigators will need to con-
sider adjusting analyses for other concomitant 
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infections, such as those affecting the gastroin-
testinal tract, that fuel HIV replication.
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The authors reply: Our study was a proof-of-
concept trial and so did not allow prediction of 
the effect of HSV suppressive therapy as a public 
health intervention to prevent the transmission 
of HIV. Available data regarding resistance to acy-
clovir are reassuring. The occurrence of acyclovir-
resistant HSV-2 strains in HIV-infected patients 
(4 to 7%) has not increased during the past two 
decades in Western countries, despite the fre-
quent use of acyclovir and valacyclovir.1 Instead, 
resistance to acyclovir could be declining, since 
the use of highly active antiretroviral therapy has 
become widespread.2 When such resistance oc-
curs, it is not predictive of clinical failure.3 In 
addition, the occurrence of genital ulceration dur-
ing the course of HSV suppressive therapy does 
not necessarily mean that the causative strain is 
resistant to acyclovir. We agree that in the absence 
of second-line therapy in resource-constrained 
countries (and considering the paucity of data 
available to date), the importance of resistance to 
acyclovir should be investigated further. However, 
even if such resistance is confirmed, it is unlikely 
to counterbalance the potential positive effect of 
HSV suppressive therapy on HIV-1 disease pro-
gression and transmission.
The HIV-1 plasma viral load in the placebo 
group increased slightly during our study, but we 
doubt this rise was due to HIV-unrelated gastro-
intestinal diseases. Several women reported hav-
1.
2.
ing more than one symptom, so the P value cal-
culated by Dr. Eisenhut needs modification. In 
fact, the proportion of women who reported at 
least one gastrointestinal symptom tended to be 
higher in the placebo group (38.2%) than in the 
valacyclovir group (25.0%) but without reaching 
statistical significance (P = 0.10). Valacyclovir and 
acyclovir have been used for decades with a safety 
profile similar to that of placebo.4 The hypothesis 
by Brenchley et al.5 that a sustained systemic im-
mune activation is fueled by intestinal bacteria 
through a translocation mechanism is based on 
the commensal enteric f lora and not on patho-
gens. It is unlikely that this mechanism could be 
altered or enhanced by the intake of valacyclovir. 
It should also be noted that our primary outcome 
was genital HIV viral load, and there was little 
difference in this outcome in the placebo group 
before randomization and after randomization 
(mean number of log10 copies per milliliter, 2.97 
and 3.02, respectively).
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Coronary Microvascular Dysfunction
To the Editor: Camici and Crea (Feb. 22 issue)1 
review the different causes and mechanisms of 
coronary microvascular dysfunction. However, 
coronary microvascular dysfunction due to aging 
deserves further comment. Age is a recognized 
risk factor for cardiovascular disease, and senes-
cence is associated with morphologic and func-
tional changes in the coronary microvasculature.2 
Studies in animals have shown that coronary flow 
reserve and the endothelium-dependent dilatation 
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